Eli Lilly and Company (NYSE:LLY - Get Free Report) had its price objective hoisted by stock analysts at Barclays from $1,400.00 to $1,550.00 in a research report issued on Monday, Benzinga reports. The brokerage currently has an "overweight" rating on the stock. Barclays's target price suggests a potential upside of 6.28% from the company's previous close.
A number of other equities analysts also recently commented on the stock. Argus boosted their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a "buy" rating in a research note on Friday, October 30th. The Goldman Sachs Group reaffirmed a "buy" rating and set a $1,413.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, October 20th. Sanford C. Bernstein reaffirmed an "outperform" rating and set a $1,450.00 target price on shares of Eli Lilly and Company in a research report on Monday, October 26th. Guggenheim lifted their price target on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a "buy" rating in a report on Friday, September 18th. Finally, Morgan Stanley boosted their price target on Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the stock an "overweight" rating in a research report on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of "Moderate Buy" and an average target price of $1,422.00.
Read Our Latest Stock Report on LLY
Eli Lilly and Company Stock Up 1.0%
NYSE LLY traded up $14.84 during trading on Monday, reaching $1,458.34. 589,509 shares of the company's stock traded hands, compared to its average volume of 2,945,998. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. The firm has a market cap of $1.37 trillion, a price-to-earnings ratio of 47.44, a price-to-earnings-growth ratio of 1.73 and a beta of 0.40. The company's 50 day simple moving average is $1,242.25 and its two-hundred day simple moving average is $1,110.30. Eli Lilly and Company has a 12-month low of $850.51 and a 12-month high of $1,475.25.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. During the same quarter in the previous year, the business posted $7.02 EPS. The company's quarterly revenue was up 38.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.
Insider Activity at Eli Lilly and Company
In related news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the sale, the executive vice president owned 4,137 shares of the company's stock, valued at $5,802,225.24. This represents a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Eli Lilly and Company
Several institutional investors and hedge funds have recently bought and sold shares of the company. Bank of America Corp DE purchased a new stake in shares of Eli Lilly and Company during the second quarter worth about $13,522,666,000. Jupiter Topco LLC acquired a new position in shares of Eli Lilly and Company during the second quarter valued at about $4,667,180,000. Corient Private Wealth LP acquired a new position in shares of Eli Lilly and Company during the second quarter valued at about $764,116,000. BlackRock Inc. raised its position in shares of Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock valued at $81,009,981,000 after purchasing an additional 1,046,558 shares during the last quarter. Finally, State Street Corp raised its position in shares of Eli Lilly and Company by 1.7% in the 3rd quarter. State Street Corp now owns 36,848,565 shares of the company's stock valued at $42,636,738,000 after purchasing an additional 632,811 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.
Eli Lilly and Company Company Profile
(
Get Free Report)
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company's medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.